Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Wasatch Global Investors, an asset management company, released its “Wasatch Small Cap Growth Strategy” third-quarter 2024 ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

Would you please address the dangers of untreated sleep apnea? Also, what do people do when they are unable to tolerate a CPAP (continuous positive airway pressure) ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

ResMed's Chief Medical Officer has suggested doctors will prescribe using both drugs and devices such as his company makes together to help sleep apnea suffers. Shares of ResMed (RMD) and Inspire ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.